Keyphrases
Radiotherapy
100%
Carboplatin
100%
Phase I Study
100%
Pemetrexed
100%
Locally Advanced
100%
Advanced Non-small Cell Lung Carcinoma
100%
Dose Level
71%
Oligometastatic
57%
Non-small Cell Lung Cancer (NSCLC)
42%
Dose-limiting Toxicity
28%
Local-regional
14%
Sepsis
14%
Stage III Disease
14%
Toxicity Grades
14%
Esophagitis
14%
Pneumonitis
14%
One Dose
14%
Follow-up Time
14%
Trial Registration
14%
Starting Dose
14%
3-cycle
14%
Stage IV Disease
14%
Median Survival Time
14%
Regional Response
14%
Toxicity Analysis
14%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Carboplatin
100%
Pemetrexed
100%
Radiation Therapy
100%
Diseases
28%
Sepsis
14%
Pneumonia
14%
Esophagitis
14%
Median Survival Time
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Carboplatin
100%
Pemetrexed
100%
Diseases
28%
Sepsis
14%
Esophagitis
14%
Pneumonia
14%
Median Survival Time
14%